Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Nevus, Sebaceous of Jadassohn 2Oncogenic osteomalacia 1

Interventions

Cyclophosphamide 910Carboplatin 788pembrolizumab 747Paclitaxel 744Bevacizumab 716Cisplatin 709Gemcitabine 621Docetaxel 584Rituximab 558Radiotherapy 548Dexamethasone 511Nivolumab 491Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 339Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × burosumab × Clear all
NCT02304367 2024-05-06

Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)

Kyowa Kirin Co., Ltd.

Phase 2 Completed
17 enrolled 66 charts

Oncogenic osteomalacia, Nevus, Sebaceous of Jadassohn

NCT04320316 2022-10-07

ENS

University of Alabama at Birmingham

Phase 4 Completed
1 enrolled 10 charts

Nevus, Sebaceous of Jadassohn

Data powered by HemOnc (CC BY 4.0) Colophon âš¡